Treatment of diabetes with glucagon-like peptide-1 gene therapy

2010 ◽  
Vol 10 (12) ◽  
pp. 1681-1692 ◽  
Author(s):  
Michael J Riedel ◽  
Timothy J Kieffer
Keyword(s):  
Gene Therapy ◽  
Treatment Of Diabetes ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Liraglutide for psychiatric disorders: clinical evidence and challenges

2018 ◽  
Vol 36 (2) ◽  
Author(s):  
Mehmet Akif Camkurt ◽  
Luca Lavagnino ◽  
Xiang Y. Zhang ◽  
Antonio L Teixeira
Keyword(s):  
Risk Factors ◽  
Psychiatric Disorders ◽  
Clinical Evidence ◽  
Preclinical Studies ◽  
Potential Candidate ◽  
Obesity And Diabetes ◽  
Treatment Of Diabetes ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Diabetes And Obesity

Abstract Obesity and diabetes are both risk factors and consequences of psychiatric disorders. Glucagon like peptide 1 (GLP-1) receptor agonists such as liraglutide are widely used in the treatment of diabetes and obesity. There are considerable amounts of preclinical studies showing the effects of liraglutide on promotion of neurogenesis, while preventing apoptosis and oxidation. Preliminary clinical evidence has suggested that liraglutide could decrease weight gain, improve cognition and prevent cognitive decline. Accordingly, liraglutide has been regarded as a potential candidate for the management of psychiatric disorders. Herein, we will discuss the association between obesity/diabetes and psychiatric disorders, and the emerging use of liraglutide in psychiatry.

Molecular docking studies and 2D analyses of DPP-4 inhibitors as candidates in the treatment of diabetes

2015 ◽  
Vol 11 (11) ◽  
pp. 3188-3193 ◽  
Author(s):  
Simone Queiroz Pantaleão ◽  
Vinicius Gonçalves Maltarollo ◽  
Sheila Cruz Araujo ◽  
Jadson Castro Gertrudes ◽  
Kathia Maria Honorio
Keyword(s):  
Molecular Docking ◽  
Glycemic Control ◽  
Gastric Inhibitory Polypeptide ◽  
Docking Studies ◽  
Molecular Docking Studies ◽  
Insulin Levels ◽  
Biological Target ◽  
Treatment Of Diabetes ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

DPP-4 is an important biological target related to the treatment of diabetes since some inhibitors can lead to an increase in the insulin levels and the prolonged activity of glucagon-like peptide-1 and gastric inhibitory polypeptide, being effective in glycemic control.

scholarly journals Glucose-Responsive Microneedle Patches for Diabetes Treatment

2018 ◽  
Vol 13 (1) ◽  
pp. 41-48 ◽  
Author(s):  
Guojun Chen ◽  
Jicheng Yu ◽  
Zhen Gu
Keyword(s):  
Drug Delivery ◽  
Blood Glucose ◽  
Release Kinetics ◽  
Blood Glucose Control ◽  
Diabetes Therapy ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Treatment Of Diabetes ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Antidiabetic therapeutics, including insulin as well as glucagon-like peptide 1 (GLP-1) and its analogs, are essential for people with diabetes to regulate their blood glucose levels. Nevertheless, conventional treatments based on hypodermic administration is commonly associated with poor blood glucose control, a lack of patient compliance, and a high risk of hypoglycemia. Closed-loop drug delivery strategies, also known as self-regulated administration, which can intelligently govern the drug release kinetics in response to the fluctuation in blood glucose levels, show tremendous promise in diabetes therapy. In the meantime, the advances in the development and use of microneedle (MN)-array patches for transdermal drug delivery offer an alternative method to conventional hypodermic administration. Hence, glucose-responsive MN-array patches for the treatment of diabetes have attracted increasing attentions in recent years. This review summarizes recent advances in glucose-responsive MN-array patch systems. Their opportunities and challenges for clinical translation are also discussed.

scholarly journals PYY, a Therapeutic Option for Type 2 Diabetes?

2020 ◽  
Vol 13 ◽  
pp. 117955141989298 ◽  
Author(s):  
Claudia Guida ◽  
Reshma Ramracheya
Keyword(s):  
Current Knowledge ◽  
Therapeutic Option ◽  
Gut Hormones ◽  
Islet Function ◽  
Appetite Regulation ◽  
Treatment Of Diabetes ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Lines Of Evidence

Metabolic surgery leads to rapid and effective diabetes reversal in humans, by weight-independent mechanisms. The crucial improvement in pancreatic islet function observed after surgery is induced by alteration in several factors, including gut hormones. In addition to glucagon-like peptide 1 (GLP-1), increasing lines of evidence show that peptide tyrosine tyrosine (PYY) plays a key role in the metabolic benefits associated with the surgery, ranging from appetite regulation to amelioration of islet secretory properties and survival. Here, we summarize the current knowledge and the latest advancements in the field, which pitch a strong case for the development of novel PYY-based therapy for the treatment of diabetes.

scholarly journals Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes

Gene Therapy ◽  
2006 ◽  
Vol 14 (1) ◽  
pp. 38-48 ◽  
Author(s):  
G B Parsons ◽  
D W Souza ◽  
H Wu ◽  
D Yu ◽  
S G Wadsworth ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Type Ii Diabetes ◽  
Ectopic Expression ◽  
Type Ii ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1
Sign in / Sign up

Export Citation Format

Share Document